molecular glues
| 3 min read
Bristol Myers Squibb has initiated a phase 1 study of BMS-986506, a cereblon E3 ligase modulator jointly developed with Evotec, triggering a $10 million milestone.
| 4 min read
A gene therapy trial halted after a child’s death, a CRISPR test to detect tuberculosis, a new device for antisense therapies, and more led the news this week.
| 4 min read
Live-cell kinetic assays provide time-resolved insights into degrader pharmacology, supporting both lead prioritization and translational modeling.
| 4 min read
A new platform may finally unlock the rules behind molecular glue degraders, turning chance discoveries into programmable therapeutics.
| 5 min read
Advances in screening and protein targeting are reviving interest in molecular glues as a strategy to tackle previously undruggable diseases.
Page 1 of 1 - 5 Total Items
